Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, the Netherlands.
Liver and Biliopancreatic Disorders, University Hospital Gasthuisberg, KU Leuven, Leuven, Belgium.
Gastrointest Endosc. 2015 May;81(5):1197-203. doi: 10.1016/j.gie.2014.10.026. Epub 2015 Feb 7.
Self-expandable metal stents (SEMSs) are increasingly used for the treatment of benign biliary strictures (BBSs). A new fully covered SEMS (FCSEMS) with flared ends and high conformability was designed to prevent migration of the stent.
To evaluate the efficacy of a novel FCSEMS with antimigration features.
Prospective cohort study.
Five hospitals in the Netherlands and Belgium.
Consecutive patients with BBS.
FCSEMS placement for 3 months.
Initial and long term clinical success, stent migration rate and safety.
Thirty-eight patients (24 men; mean age, 53 ± 16 years) were included. Stent placement was technically successful in 37 patients (97%). Two patients died of an unrelated cause before stent removal, and no data on these patients were available on stricture resolution. Initial clinical success was achieved in 28 of 35 patients (80%). During follow-up after stent removal, a symptomatic recurrent stricture developed in 6 of 28 patients (21%). Overall, the long-term clinical success rate was 63% (22 of 35 patients). Stent migration occurred in 11 of 35 patients (31%), including 5 symptomatic (14%) and 6 asymptomatic (17%) migrations. In total, 11 serious adverse events occurred in 10 patients (29%), with cholangitis (n = 5) being most common.
Nonrandomized study design.
Good initial clinical success was achieved after placement of this novel FCSEMS, but stricture recurrence was in the upper range compared with other FCSEMSs. The antimigration design could not prevent migration in a significant number of patients with a persisting stricture.
自膨式金属支架(SEMS)越来越多地用于治疗良性胆道狭窄(BBS)。一种新型完全覆膜自膨式金属支架(FCSEMS)具有喇叭口状的两端和高顺应性,旨在防止支架移位。
评估具有抗迁移功能的新型 FCSEMS 的疗效。
前瞻性队列研究。
荷兰和比利时的五家医院。
BBS 连续患者。
FCSEMS 放置 3 个月。
初始和长期临床成功率、支架迁移率和安全性。
38 例患者(24 例男性;平均年龄 53 ± 16 岁)纳入研究。37 例患者(97%)支架置入技术成功。2 例患者在支架取出前因与无关原因死亡,这些患者的狭窄缓解数据无法获得。28 例患者中有 28 例(80%)获得初始临床成功。支架取出后的随访期间,6 例患者(21%)出现症状性复发性狭窄。总体而言,35 例患者中有 22 例(63%)长期临床成功率。35 例患者中有 11 例(31%)支架移位,其中 5 例(14%)有症状,6 例(17%)无症状。共有 10 例患者(29%)发生 11 例严重不良事件,其中最常见的是胆管炎(n = 5)。
非随机研究设计。
这种新型 FCSEMS 放置后获得了良好的初始临床成功率,但与其他 FCSEMS 相比,狭窄复发率处于较高水平。对于存在持续性狭窄的患者,抗迁移设计无法阻止支架迁移。